Myeloproliferative Disorders Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Conditions: Myeloproliferative Neoplasm; Secondary Leukemia Interventions: Other: Multiomic characterization; Other: In vitro drug screening Sponsors: University Hospital, Angers; University Hospital, Brest; Institut Paoli-Calmettes; Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Condition: Myeloproliferative Neoplasm Intervention: Biological: Assessment of the epigenetic age Sponsor: University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Conditions: Myeloproliferative Neoplasm; Secondary Leukemia Interventions: Other: Multiomic characterization; Other: In vitro drug screening Sponsors: University Hospital, Angers; University Hospital, Brest; Institut Paoli-Calmettes; Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Condition: Myeloproliferative Neoplasm Intervention: Biological: Assessment of the epigenetic age Sponsor: University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Conditions: Myeloproliferative Neoplasm; Secondary Leukemia Interventions: Other: Multiomic characterization; Other: In vitro drug screening Sponsors: University Hospital, Angers; University Hospital, Brest; Institut Paoli-Calmettes; Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Condition: Myeloproliferative Neoplasm Intervention: Biological: Assessment of the epigenetic age Sponsor: University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Conditions: Myeloproliferative Neoplasm; Secondary Leukemia Interventions: Other: Multiomic characterization; Other: In vitro drug screening Sponsors: University Hospital, Angers; University Hospital, Brest; Institut Paoli-Calmettes; Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Condition: Myeloproliferative Neoplasm Intervention: Biological: Assessment of the epigenetic age Sponsor: University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Conditions: Myeloproliferative Neoplasm; Secondary Leukemia Interventions: Other: Multiomic characterization; Other: In vitro drug screening Sponsors: University Hospital, Angers; University Hospital, Brest; Institut Paoli-Calmettes; Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Condition: Myeloproliferative Neoplasm Intervention: Biological: Assessment of the epigenetic age Sponsor: University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Conditions: Myeloproliferative Neoplasm; Secondary Leukemia Interventions: Other: Multiomic characterization; Other: In vitro drug screening Sponsors: University Hospital, Angers; University Hospital, Brest; Institut Paoli-Calmettes; Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Condition: Myeloproliferative Neoplasm Intervention: Biological: Assessment of the epigenetic age Sponsor: University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Conditions: Myeloproliferative Neoplasm; Secondary Leukemia Interventions: Other: Multiomic characterization; Other: In vitro drug screening Sponsors: University Hospital, Angers; University Hospital, Brest; Institut Paoli-Calmettes; Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Condition: Myeloproliferative Neoplasm Intervention: Biological: Assessment of the epigenetic age Sponsor: University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies
Conditions: Myeloproliferative Neoplasm; Secondary Leukemia Interventions: Other: Multiomic characterization; Other: In vitro drug screening Sponsors: University Hospital, Angers; University Hospital, Brest; Institut Paoli-Calmettes; Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials
